Literature DB >> 7212758

Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3.

C R Scriver, T Reade, F Halal, T Costa, D E Cole.   

Abstract

We diagnosed non X-linked hypophosphataemic bone disease in a 38-month-old girl. Findings included: genu varum, shortened stature, fasting hypophosphataemia (2.3-2.5 mg/100 ml; 0.74-0.81 mmol/l), diminished theoretical renal threshold for phosphate (TmP/GFR), and osteomalacia without rickets. One patient (the father) had fasting hypophosphataemia (2.3-2.7 mg/100 ml; 0.74-0.87 mmol/l) and low TmP/GFR without osteomalacia or shortened stature. Treatment of the girl with 1,25-(OH)2D3 (1 microgram a day) raised the level of serum phosphorus, improved tubular reabsorption of phosphate, and healed the bone deformity; this combination of responses is not present in X-linked hypophosphataemia. There was no correction of hypophosphataemia or TmP/GFR with 1,25-(OH)2D3 treatment (1-3 micrograms a day) in the father.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7212758      PMCID: PMC1627154          DOI: 10.1136/adc.56.3.203

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  The urine cyclic AMP response to parathyroid extract (PTE) administration in normal subjects and patients with parathyroid dysfunction.

Authors:  J R Tucci; R S Perlstein; L E Kopp
Journal:  Metabolism       Date:  1979-08       Impact factor: 8.694

3.  A study of the behaviour of some sixty amino-acids and other ninhydrin-reacting substances on phenol-;collidine' filter-paper chromatograms, with notes as to the occurrence of some of them in biological fluids.

Authors:  C E Dent
Journal:  Biochem J       Date:  1948       Impact factor: 3.857

4.  Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets.

Authors:  A S Brickman; J W Coburn; K Kurokawa; J E Bethune; H E Harrison; A W Norman
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

5.  X-linked hypophosphataemic rickets: Inadequate therapeutic response to 1,25-dihydroxycholecalciferol.

Authors:  F H Glorieux; M F Holick; C R Scriver; H F DeLuca
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

6.  Renal adaptation to phosphate deprivation in the Hyp mouse with X-linked hypophosphatemia.

Authors:  H S Tenenhouse; C R Scriver
Journal:  Can J Biochem       Date:  1979-06

7.  Evidence for an intrinsic renal tubular defect in mice with genetic hypophosphatemic rickets.

Authors:  L D Cowgill; S Goldfarb; K Lau; E Slatopolsky; Z S Agus
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

8.  Loss of a parathyroid hormone-sensitive component of phosphate transport in X-linked hypophosphatemia.

Authors:  F Glorieux; C R Scriver
Journal:  Science       Date:  1972-03-03       Impact factor: 47.728

9.  The defect in transcellular transport of phosphate in the nephron is located in brush-border membranes in X-linked hypophosphatemia (Hyp mouse model).

Authors:  H S Tenenhouse; C R Scriver
Journal:  Can J Biochem       Date:  1978-06

10.  Radioimmunoassay of human parathyroid hormone in serum.

Authors:  C D Arnaud; H S Tsao; T Littledike
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

View more
  7 in total

Review 1.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  X-linked hypophosphatemia: the mutant gene is expressed in teeth as well as in kidney.

Authors:  E D Shields; C R Scriver; T Reade; T M Fujiwara; K Morgan; A Ciampi; S Schwartz
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

Review 3.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

Review 4.  Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation.

Authors:  Murat Bastepe; Harald Jüppner
Journal:  Rev Endocr Metab Disord       Date:  2008-03-26       Impact factor: 6.514

5.  Adult hypophosphatemic osteomalacia: report of two cases.

Authors:  H Rico; F Gomez-Castresana; E R Hernandez; J A Matute; J Torrubiano; M Nunez-Torrón
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

6.  Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet.

Authors:  J Brodehl; A Krause; P F Hoyer
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

7.  Therapeutic management of hypophosphatemic rickets from infancy to adulthood.

Authors:  Agnès Linglart; Martin Biosse-Duplan; Karine Briot; Catherine Chaussain; Laure Esterle; Séverine Guillaume-Czitrom; Peter Kamenicky; Jerome Nevoux; Dominique Prié; Anya Rothenbuhler; Philippe Wicart; Pol Harvengt
Journal:  Endocr Connect       Date:  2014-03-14       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.